High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya.
about
Clearance of asymptomatic P. falciparum Infections Interacts with the number of clones to predict the risk of subsequent malaria in Kenyan childrenIncidence of Severe Malaria Syndromes and Status of Immune Responses among Khat Chewer Malaria Patients in EthiopiaA phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720Micro-epidemiological structuring of Plasmodium falciparum parasite populations in regions with varying transmission intensities in AfricaOpsonising antibodies to P. falciparum merozoites associated with immunity to clinical malariaAcquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum.Heritability of antibody isotype and subclass responses to Plasmodium falciparum antigensThe quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malariaFunctional memory B cells and long-lived plasma cells are generated after a single Plasmodium chabaudi infection in mice.The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis.3D analysis of the TCR/pMHCII complex formation in monkeys vaccinated with the first peptide inducing sterilizing immunity against human malaria.Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodiesAcquisition of antibody isotypes against Plasmodium falciparum blood stage antigens in a birth cohortStable and unstable malaria hotspots in longitudinal cohort studies in Kenya.High Sporozoite Antibody Titers in Conjunction with Microscopically Detectable Blood Infection Display Signatures of Protection from Clinical MalariaEpstein-Barr virus but not cytomegalovirus is associated with reduced vaccine antibody responses in Gambian infantsAllele-specific antibodies to Plasmodium falciparum merozoite surface protein-2 and protection against clinical malaria.Boosting antibody responses to Plasmodium falciparum merozoite antigens in children with highly seasonal exposure to infectionDevelopment of fluorescent Plasmodium falciparum for in vitro growth inhibition assaysLong-lived Plasmodium falciparum specific memory B cells in naturally exposed Swedish travelersThe breadth, but not the magnitude, of circulating memory B cell responses to P. falciparum increases with age/exposure in an area of low transmission.Memory B cells are a more reliable archive for historical antimalarial responses than plasma antibodies in no-longer exposed children.Allelic diversity and naturally acquired allele-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 in KenyaLimited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines.Subclass responses and their half-lives for antibodies against EBA175 and PfRh2 in naturally acquired immunity against Plasmodium falciparum malaria.Lack of avidity maturation of merozoite antigen-specific antibodies with increasing exposure to Plasmodium falciparum amongst children and adults exposed to endemic malaria in Kenya.Phenotypic and functional profiling of CD4 T cell compartment in distinct populations of healthy adults with different antigenic exposureEvaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injectionAcquisition of antibodies against Plasmodium falciparum merozoites and malaria immunity in young children and the influence of age, force of infection, and magnitude of responseNatural antibody response to Plasmodium falciparum merozoite antigens MSP5, MSP9 and EBA175 is associated to clinical protection in the Brazilian Amazon.Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malariaNew antigens for a multicomponent blood-stage malaria vaccineExposure, infection, systemic cytokine levels and antibody responses in young children concurrently exposed to schistosomiasis and malaria.Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, KenyaAsymptomatic Plasmodium falciparum infection in children is associated with increased auto-antibody production, high IL-10 plasma levels and antibodies to merozoite surface protein 3.Multiple clinical episodes of Plasmodium falciparum malaria in a low transmission intensity setting: exposure versus immunity.Molecular epidemiology of malaria.Naturally Acquired Antibody Responses to Plasmodium vivax and Plasmodium falciparum Merozoite Surface Protein 1 (MSP1) C-Terminal 19 kDa Domains in an Area of Unstable Malaria Transmission in Southeast Asia.Naturally acquired antibodies to polymorphic and conserved epitopes of Plasmodium falciparum merozoite surface protein 3.Antibodies directed against merozoite surface protein-6 are induced by natural exposure to Plasmodium falciparum in a low transmission environment.
P2860
Q28477259-E49614E0-9DA6-4E9E-B4A5-9DFEE80E5E25Q28546478-324AF59D-4A1D-4898-8C81-3E51D13A5B97Q28744696-8BBD63CC-8BE2-4133-9F6A-AFFE980745F9Q29464553-4CFFD233-94F4-4463-9F5C-8FCCCAF2B74BQ31139546-1287D0ED-E3B9-4340-9C0A-46BD1BB2CB69Q33380204-0AD4F8DD-5FBB-47CE-B6B1-F3A7DC226E50Q33509282-952C6D68-E85F-4073-9D2B-F36AE9BAC780Q33512926-0A00EABB-2F8B-4350-8AED-7A8685E35832Q33518486-B7499964-743E-4C06-8AB8-773106F08640Q33526349-05374403-8CD2-4C3D-A025-3E1E9A00B52CQ33545251-333DC829-14C6-49CA-BDF9-7B406A677DEAQ33548663-5CCC9AF8-46AF-449D-9E82-D55583505117Q33621604-D071A429-D40E-4306-9AA0-996C5887FF3FQ33631268-335ED891-86E5-4760-BEB0-84C577720954Q33646573-052FAC84-BF59-42A1-89E5-8BD9A32F980DQ33754553-08590BD0-6B83-48A0-8006-B36F6867CE5CQ33760116-69366416-BAB1-4AF0-8EC9-6D2409438617Q33767397-785BCE3E-D29B-4492-8A8D-0AACE1E6454BQ33939788-2C661917-4562-4880-A4D0-F4B81D64892AQ33967206-803BD007-D63C-4444-9F12-1BBE9F586DB1Q34047037-FA79D36D-A638-4AA6-A942-770CEC3F8AAFQ34261333-3B99DE43-2E10-4B2F-A7C3-0820A53D60A8Q34290806-ED539DD4-769F-4CDE-BD17-35647767550EQ34416904-E51CCA44-4547-4E18-A0D5-7F1A3DA11CFAQ34515219-AE814C83-E850-4203-834E-4E17F79E44B0Q34541443-4C6250C4-2C12-49E6-809B-72357F447567Q34576202-8A325EF1-0F5B-4F01-A217-265974D73AFAQ34687174-910F5D34-A175-4A54-BF0B-6E4A7E609910Q34955461-8C59ADAE-5181-4882-9611-FACFE145ED82Q35076906-FD14BC9D-FC77-4C92-AE1F-973256935B05Q35213495-E28B261A-853B-4781-8D8D-83B0B63EB896Q35216634-98AC173D-C696-4BAD-AB80-0C16949F59C2Q35228686-E9033D07-DDE0-4B9D-8DF5-45F6B9FC2441Q35559418-A3CED8B8-5C04-4059-9A97-D4449CC528BEQ35568907-71BB1045-BAD9-49A3-8C51-4DA379135F01Q35628510-5B553766-302B-4517-A71D-A66DBBA05761Q35635612-05365EF5-2DAA-4C6E-9603-8909535011D8Q35964846-7DBF3661-2CD0-4855-AC84-EDAA8AD9D1C2Q35990786-1D66960E-656F-437E-B406-F7E4074102EDQ36002836-59D36E7E-41BF-46EE-8E86-7A55202C72A9
P2860
High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
High levels of serum antibodie ...... ical malaria in coastal Kenya.
@en
High levels of serum antibodie ...... ical malaria in coastal Kenya.
@nl
type
label
High levels of serum antibodie ...... ical malaria in coastal Kenya.
@en
High levels of serum antibodie ...... ical malaria in coastal Kenya.
@nl
prefLabel
High levels of serum antibodie ...... ical malaria in coastal Kenya.
@en
High levels of serum antibodie ...... ical malaria in coastal Kenya.
@nl
P2093
P50
P921
P1433
P1476
High levels of serum antibodie ...... ical malaria in coastal Kenya.
@en
P2093
Brett S Lowe
Jana S McBride
Spencer D Polley
Tabitha W Mwangi
P304
P356
10.1016/J.VACCINE.2005.06.030
P407
P577
2005-07-27T00:00:00Z